{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:48:35Z","timestamp":1791571715171,"version":"4.3.4"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.metabol.2024.156053","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T11:13:20Z","timestamp":1730114000000},"page":"156053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Evidence from clinical studies of leptin: current and future clinical applications in humans"],"prefix":"10.1016","volume":"161","author":[{"given":"Nikolaos","family":"Perakakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6505","key":"10.1016\/j.metabol.2024.156053_bb0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.metabol.2024.156053_bb0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jacc.2020.11.069","article-title":"Leptin in leanness and obesity: JACC state-of-the-art review","volume":"77","author":"Perakakis","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.156053_bb0015","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1100\/tsw.2007.117","article-title":"The physiology of obese-hyperglycemic mice [Ob\/Ob mice]","volume":"7","author":"Lindstrom","year":"2007","journal-title":"Sci World J"},{"issue":"1\u20132","key":"10.1016\/j.metabol.2024.156053_bb0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cell.2014.12.022","article-title":"Leptin and insulin act on POMC neurons to promote the browning of white fat","volume":"160","author":"Dodd","year":"2015","journal-title":"Cell"},{"issue":"4 Pt 2","key":"10.1016\/j.metabol.2024.156053_bb0025","first-page":"R1204","article-title":"Leptin increases energy expenditure and selectively promotes fat metabolism in Ob\/Ob mice","volume":"272","author":"Hwa","year":"1997","journal-title":"Am J Phys"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ng0996-95","article-title":"Leptin activation of Stat3 in the hypothalamus of wild-type and Ob\/Ob mice but not db\/db mice","volume":"14","author":"Vaisse","year":"1996","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.metabol.2024.156053_bb0035","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2337\/diabetes.48.6.1264","article-title":"Acute intravenous leptin infusion increases glucose turnover but not skeletal muscle glucose uptake in Ob\/Ob mice","volume":"48","author":"Burcelin","year":"1999","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2024.156053_bb0040","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ng0396-318","article-title":"Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin","volume":"12","author":"Chehab","year":"1996","journal-title":"Nat Genet"},{"issue":"6748","key":"10.1016\/j.metabol.2024.156053_bb0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.metabol.2024.156053_bb0050","doi-asserted-by":"crossref","first-page":"8878","DOI":"10.1073\/pnas.94.16.8878","article-title":"Physiological response to long-term peripheral and central leptin infusion in lean and obese mice","volume":"94","author":"Halaas","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6588","key":"10.1016\/j.metabol.2024.156053_bb0055","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/382250a0","article-title":"Role of leptin in the neuroendocrine response to fasting","volume":"382","author":"Ahima","year":"1996","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0060","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/diab.45.10.1446","article-title":"The weight-reducing effect of an intracerebroventricular bolus injection of leptin in genetically obese fa\/fa rats. Reduced sensitivity compared with lean animals","volume":"45","author":"Cusin","year":"1996","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0065","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199602013340503","article-title":"Serum immunoreactive-leptin concentrations in normal-weight and obese humans","volume":"334","author":"Considine","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0070","first-page":"1293","article-title":"The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure","volume":"82","author":"Kennedy","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.metabol.2024.156053_bb0075","first-page":"3419","article-title":"Effect of fasting on serum leptin in normal human subjects","volume":"81","author":"Boden","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"5223","key":"10.1016\/j.metabol.2024.156053_bb0080","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.7624777","article-title":"Weight-reducing effects of the plasma protein encoded by the obese gene","volume":"269","author":"Halaas","year":"1995","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.metabol.2024.156053_bb0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cmet.2013.12.008","article-title":"Fasting: molecular mechanisms and clinical applications","volume":"19","author":"Longo","year":"2014","journal-title":"Cell Metab"},{"issue":"16","key":"10.1016\/j.metabol.2024.156053_bb0090","article-title":"The circulating metabolome of human starvation. JCI","volume":"3","author":"Steinhauser","year":"2018","journal-title":"Insight"},{"issue":"9","key":"10.1016\/j.metabol.2024.156053_bb0095","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1172\/JCI200317490","article-title":"The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men","volume":"111","author":"Chan","year":"2003","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1016\/j.metabol.2024.156053_bb0100","doi-asserted-by":"crossref","first-page":"8481","DOI":"10.1073\/pnas.0505429103","article-title":"Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans","volume":"103","author":"Chan","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0105","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1038\/s41467-020-18885-9","article-title":"Leptin alters energy intake and fat mass but not energy expenditure in lean subjects","volume":"11","author":"Chrysafi","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.metabol.2024.156053_bb0110","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/dom.13572","article-title":"Follistatins in glucose regulation in healthy and obese individuals","volume":"21","author":"Perakakis","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3297","article-title":"Metabolic regulation of activins in healthy individuals and in obese patients undergoing bariatric surgery","volume":"36","author":"Perakakis","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0120","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1210\/jc.2018-01056","article-title":"Physiology of Activins\/Follistatins: associations with metabolic and anthropometric variables and response to exercise","volume":"103","author":"Perakakis","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156053_bb0125","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.metabol.2018.05.003","article-title":"Regulation of the activins-follistatins-inhibins axis by energy status: impact on reproductive function","volume":"85","author":"Perakakis","year":"2018","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2024.156053_bb0130","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1210\/clinem\/dgz172","article-title":"Targeted analysis of three hormonal systems identifies molecules associated with the presence and severity of NAFLD","volume":"105","author":"Polyzos","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12933-024-02264-5","article-title":"Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity","volume":"23","author":"Boutari","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0140","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1038\/s41467-024-49366-y","article-title":"Total and H-specific GDF-15 levels increase in caloric deprivation independently of leptin in humans","volume":"15","author":"Chrysafi","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2024.156053_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116809","article-title":"Overview of growth differentiation factor 15 (GDF15) in metabolic diseases","volume":"176","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2024.156053_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155237","article-title":"Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity","volume":"133","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156053_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155694","article-title":"Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: a multicenter observational study","volume":"148","author":"Valenzuela-Vallejo","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156053_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117313","article-title":"Lipid-lowering in diabetes: an update","volume":"394","author":"Chait","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2024.156053_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154392","article-title":"Circulating profile of Activin-Follistatin-inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment","volume":"113","author":"Bouzoni","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156053_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155265","article-title":"PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic doses","volume":"134","author":"Bouzoni","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156053_bb0175","article-title":"Lipodystrophy syndromes","author":"Mantzoros","year":"2024","journal-title":"Uptodate"},{"key":"10.1016\/j.metabol.2024.156053_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155984","article-title":"Longitudinal proteomics of leptin treatment in humans with acute and chronic energy deficiency-induced hypoleptinemia reveal novel, mainly immune-related, pleiotropic effects","volume":"159","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.metabol.2024.156053_bb0185","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/00003088-200847110-00006","article-title":"Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity","volume":"47","author":"Chan","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0190","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1210\/endrev\/bnae011","article-title":"Relative energy deficiency in sport (REDs): endocrine manifestations, pathophysiology and treatments","volume":"45","author":"Angelidi","year":"2024","journal-title":"Endocr Rev"},{"issue":"16","key":"10.1016\/j.metabol.2024.156053_bb0195","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1073\/pnas.1015674108","article-title":"Leptin is an effective treatment for hypothalamic amenorrhea","volume":"108","author":"Chou","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0200","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa040388","article-title":"Recombinant human leptin in women with hypothalamic amenorrhea","volume":"351","author":"Welt","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.metabol.2024.156053_bb0205","doi-asserted-by":"crossref","first-page":"E2529","DOI":"10.1210\/jc.2014-2774","article-title":"Leptin therapy alters appetite and neural responses to food stimuli in brain areas of leptin-sensitive subjects without altering brain structure","volume":"99","author":"Farr","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.metabol.2024.156053_bb0210","doi-asserted-by":"crossref","first-page":"E818","DOI":"10.1073\/pnas.1214554110","article-title":"Selective capacity of metreleptin administration to reconstitute CD4+ T-cell number in females with acquired hypoleptinemia","volume":"110","author":"Matarese","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.metabol.2024.156053_bb0215","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.metabol.2011.05.016","article-title":"Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women","volume":"60","author":"Sienkiewicz","year":"2011","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.metabol.2024.156053_bb0220","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S2215-0366(15)00356-9","article-title":"Anorexia nervosa: aetiology, assessment, and treatment","volume":"2","author":"Zipfel","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0225","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.tem.2021.07.010","article-title":"Reframing anorexia nervosa as a metabo-psychiatric disorder","volume":"32","author":"Bulik","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156053_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104807","article-title":"The role of hypoleptinemia in the psychological and behavioral adaptation to starvation: implications for anorexia nervosa","volume":"141","author":"Hebebrand","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"issue":"7","key":"10.1016\/j.metabol.2024.156053_bb0235","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1210\/jcem.86.7.7685","article-title":"Serum leptin, gonadotropin, and testosterone concentrations in male patients with anorexia nervosa during weight gain","volume":"86","author":"Wabitsch","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0240","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40337-023-00744-9","article-title":"Endocrine complications of anorexia nervosa","volume":"11","author":"Haines","year":"2023","journal-title":"J Eat Disord"},{"issue":"7","key":"10.1016\/j.metabol.2024.156053_bb0245","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2213-8587(13)70180-3","article-title":"Endocrine consequences of anorexia nervosa","volume":"2","author":"Misra","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0250","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00787-021-01778-7","article-title":"Rapid amelioration of anorexia nervosa in a male adolescent during metreleptin treatment including recovery from hypogonadotropic hypogonadism","volume":"31","author":"Antel","year":"2022","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.metabol.2024.156053_bb0255","article-title":"Reward processing during monetary incentive delay task after leptin substitution in lipodystrophy-an fMRI case series","volume":"7(6):bvad052","author":"Schlogl","year":"2023","journal-title":"J Endocr Soc"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0260","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1210\/clinem\/dgae149","article-title":"Classification of congenital leptin deficiency","volume":"109","author":"von Schnurbein","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6636","key":"10.1016\/j.metabol.2024.156053_bb0265","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/43185","article-title":"Congenital leptin deficiency is associated with severe early-onset obesity in humans","volume":"387","author":"Montague","year":"1997","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.metabol.2024.156053_bb0270","article-title":"High morbidity and mortality in children with untreated congenital deficiency of leptin or its receptor","volume":"4","author":"Saeed","year":"2023","journal-title":"Cell Rep Med"},{"issue":"5843","key":"10.1016\/j.metabol.2024.156053_bb0275","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.1144599","article-title":"Leptin regulates striatal regions and human eating behavior","volume":"317","author":"Farooqi","year":"2007","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.metabol.2024.156053_bb0280","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI0215693","article-title":"Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine\/metabolic dysfunction of human congenital leptin deficiency","volume":"110","author":"Farooqi","year":"2002","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0285","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1210\/jc.2004-0376","article-title":"Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy","volume":"89","author":"Gibson","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.metabol.2024.156053_bb0290","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1210\/clinem\/dgaa251","article-title":"Leptin-mediated changes in the human metabolome","volume":"105","author":"Lawler","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2024.156053_bb0295","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1210\/jcem.87.2.8241","article-title":"Different presentation of bone mass in mice and humans with congenital leptin deficiency","volume":"87","author":"Ozata","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.metabol.2024.156053_bb0300","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1210\/jc.2018-02730","article-title":"Comorbidities and survival in patients with lipodystrophy: an international chart review study","volume":"104","author":"Akinci","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2024.156053_bb0305","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2016-2271","article-title":"Clinical features and Management of non-HIV-related lipodystrophy in children: a systematic review","volume":"102","author":"Gupta","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156053_bb0310","article-title":"Effects of Metreleptin on patient outcomes and quality of life in generalized and partial lipodystrophy","volume":"5(4):bvab019","author":"Cook","year":"2021","journal-title":"J Endocr Soc"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0315","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2024.156053_bb0320","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/diabetes.54.7.1994","article-title":"Long-term efficacy of leptin replacement in patients with generalized lipodystrophy","volume":"54","author":"Javor","year":"2005","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0325","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.metabol.2003.10.019","article-title":"Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy","volume":"53","author":"Moran","year":"2004","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0330","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgab269","article-title":"Leptin decreases energy expenditure despite increased thyroid hormone in patients with lipodystrophy","volume":"106","author":"Grover","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2024.156053_bb0335","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1210\/jcem.87.7.8591","article-title":"Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy","volume":"87","author":"Oral","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2024.156053_bb0340","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1210\/jc.2005-1220","article-title":"Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy","volume":"91","author":"Oral","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.metabol.2024.156053_bb0345","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cell.2015.07.007","article-title":"Leptin does not mediate hypertension associated with human obesity","volume":"162","author":"Brown","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.metabol.2024.156053_bb0350","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.metabol.2024.156053_bb0355","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.metabol.2024.156053_bb0360","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0365","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad445","article-title":"Leptin decreases gluconeogenesis and Gluconeogenic substrate availability in patients with lipodystrophy","volume":"109","author":"Quaye","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"10.1016\/j.metabol.2024.156053_bb0370","article-title":"Leptin decreases de novo lipogenesis in patients with lipodystrophy. JCI","volume":"5","author":"Baykal","year":"2020","journal-title":"Insight"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0375","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cmet.2016.04.011","article-title":"Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk","volume":"23","author":"Stern","year":"2016","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.metabol.2024.156053_bb0380","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1507\/endocrj.EJ21-0110","article-title":"Practice guideline for lipodystrophy syndromes-clinically important diseases of the Japan Endocrine Society (JES) preface","volume":"68","author":"Tanaka","year":"2021","journal-title":"Endocr J"},{"issue":"11","key":"10.1016\/j.metabol.2024.156053_bb0385","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1210\/jc.2015-2589","article-title":"A report of three cases with acquired generalized lipodystrophy with distinct autoimmune conditions treated with Metreleptin","volume":"100","author":"Lebastchi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0390","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1515\/jpem-2018-0356","article-title":"Acquired partial lipodystrophy with metabolic disease in children following hematopoietic stem cell transplantation: a report of two cases and a review of the literature","volume":"32","author":"Hosokawa","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.metabol.2024.156053_bb0395","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/js.2019-00251","article-title":"Metreleptin supplementation for improving lipid and glycemic profiles in acquired diabetes lipodystrophy: a case report","volume":"3","author":"Nagayama","year":"2019","journal-title":"Journal of the Endocrine Society"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0400","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s13256-018-1901-y","article-title":"Acquired partial lipoatrophy as graft-versus-host disease and treatment with metreleptin: two case reports","volume":"12","author":"Shibata","year":"2018","journal-title":"J Med Case Rep"},{"issue":"8","key":"10.1016\/j.metabol.2024.156053_bb0405","doi-asserted-by":"crossref","first-page":"E1493","DOI":"10.1210\/jc.2014-1353","article-title":"Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy","volume":"99","author":"Christensen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156053_bb0410","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bone.2017.03.053","article-title":"Normal bone density and trabecular bone score, but high serum sclerostin in congenital generalized lipodystrophy","volume":"101","author":"Lima","year":"2017","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.metabol.2024.156053_bb0415","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1086\/367859","article-title":"Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin","volume":"36","author":"Nagy","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.metabol.2024.156053_bb0420","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1210\/jc.2005-1545","article-title":"Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy","volume":"91","author":"Lee","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2024.156053_bb0425","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.metabol.2010.10.002","article-title":"Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study","volume":"60","author":"Magkos","year":"2011","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0430","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2008-1588","article-title":"The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia","volume":"94","author":"Mulligan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0435","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.metabol.2012.03.013","article-title":"Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome","volume":"61","author":"Sekhar","year":"2012","journal-title":"Metabolism"},{"issue":"16","key":"10.1016\/j.metabol.2024.156053_bb0440","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0445","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.ijo.0801952","article-title":"The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects","volume":"26","author":"Hukshorn","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0450","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.2337\/db10-1302","article-title":"Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes","volume":"60","author":"Mittendorfer","year":"2011","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.metabol.2024.156053_bb0455","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/db10-1791","article-title":"Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance","volume":"60","author":"Moon","year":"2011","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0460","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ajcn\/74.4.426","article-title":"Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men","volume":"74","author":"Westerterp-Plantenga","year":"2001","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.1016\/j.metabol.2024.156053_bb0465","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1463-1326.2005.00468.x","article-title":"Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial","volume":"7","author":"Zelissen","year":"2005","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.metabol.2024.156053_bb0470","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1172\/JCI25977","article-title":"Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight","volume":"115","author":"Rosenbaum","year":"2005","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.metabol.2024.156053_bb0475","first-page":"2583","article-title":"Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli","volume":"118","author":"Rosenbaum","year":"2008","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.metabol.2024.156053_bb0480","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3945\/ajcn.111.012385","article-title":"Leptin reverses declines in satiation in weight-reduced obese humans","volume":"95","author":"Kissileff","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0485","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/oby.20433","article-title":"Randomized double-blind placebo-controlled study of leptin administration after gastric bypass","volume":"21","author":"Korner","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.metabol.2024.156053_bb0490","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/978-3-031-63657-8_16","article-title":"The mechanism of leptin resistance in obesity and therapeutic perspective","volume":"1460","author":"Engin","year":"2024","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0495","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.beem.2015.08.002","article-title":"The soluble leptin receptor","volume":"29","author":"Schaab","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156053_bb0500","first-page":"9","article-title":"CB(1)R regulates soluble leptin receptor levels via CHOP, contributing to hepatic leptin resistance","author":"Drori","year":"2020","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0505","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molmet.2016.10.009","article-title":"Endospanin1 affects oppositely body weight regulation and glucose homeostasis by differentially regulating central leptin signaling","volume":"6","author":"Vauthier","year":"2017","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0510","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2337\/dc17-2132","article-title":"Antisense inhibition of protein tyrosine phosphatase 1B with IONIS-PTP-1B(Rx) improves insulin sensitivity and reduces weight in overweight patients with type 2 diabetes","volume":"41","author":"Digenio","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0515","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cmet.2019.08.005","article-title":"Partial leptin reduction as an insulin sensitization and weight loss strategy","volume":"30","author":"Zhao","year":"2019","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.metabol.2024.156053_bb0520","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintide\/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity (Silver Spring)"},{"issue":"20","key":"10.1016\/j.metabol.2024.156053_bb0525","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.0706473105","article-title":"Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies","volume":"105","author":"Roth","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0530","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin Endocrinol"},{"issue":"10403","key":"10.1016\/j.metabol.2024.156053_bb0535","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156053_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155689","article-title":"Milestones in the journey towards addressing obesity; past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery","volume":"148","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156053_bb0545","article-title":"Efficacy of Metreleptin for weight loss in overweight and obese adults with low leptin levels","volume":"67(Supplement_1):296-LB","author":"De Paoli","year":"2018","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2024.156053_bb0550","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-019-0370-1","article-title":"Dysregulation of a long noncoding RNA reduces leptin leading to a leptin-responsive form of obesity","volume":"25","author":"Dallner","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0555","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgab760","article-title":"Endogenous leptin concentrations poorly predict Metreleptin response in patients with partial lipodystrophy","volume":"107","author":"Meral","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156053_bb0560","article-title":"Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency","volume":"15(723):eadd4897","author":"Altarejos","year":"2023","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0565","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/ijo.2014.177","article-title":"Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss","volume":"39","author":"Iepsen","year":"2015","journal-title":"Int J Obes"},{"key":"10.1016\/j.metabol.2024.156053_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108899","article-title":"Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: a meta-analysis of randomized controlled trials","volume":"177","author":"Simental-Mendia","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0575","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0580","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc16-1553","article-title":"Efficacy and safety of Metreleptin therapy in patients with type 1 diabetes: a pilot study","volume":"40","author":"Vasandani","year":"2017","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.metabol.2024.156053_bb0585","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgab782","article-title":"Long-term effects of Metreleptin in Rabson-Mendenhall syndrome on Glycemia, growth, and kidney function","volume":"107","author":"Okawa","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2024.156053_bb0590","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.medj.2021.04.001","article-title":"Metreleptin therapy for nonalcoholic steatohepatitis: open-label therapy interventions in two different clinical settings","volume":"2","author":"Akinci","year":"2021","journal-title":"Med"},{"issue":"11","key":"10.1016\/j.metabol.2024.156053_bb0595","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1210\/jcem.85.11.6955","article-title":"Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men","volume":"85","author":"Hukshorn","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0600","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2337\/dc13-2040","article-title":"Effects of leptin replacement therapy on pancreatic beta-cell function in patients with lipodystrophy","volume":"37","author":"Muniyappa","year":"2014","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0605","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13612","article-title":"Liver fat as risk factor of hepatic and cardiometabolic diseases","volume":"24","author":"Demir","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.metabol.2024.156053_bb0610","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.metabol.2019.05.001","article-title":"Fatty liver in lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and\/or leptin replacement","volume":"96","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0615","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2016-3628","article-title":"Effects of Metreleptin in pediatric patients with lipodystrophy","volume":"102","author":"Brown","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0620","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh","year":"2013","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.metabol.2024.156053_bb0625","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.metabol.2024.156053_bb0630","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.cmet.2022.09.020","article-title":"Leptin increases hepatic triglyceride export via a vagal mechanism in humans","volume":"34","author":"Metz","year":"2022","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0635","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0092-8674(00)81865-6","article-title":"Targeted disruption of the melanocortin-4 receptor results in obesity in mice","volume":"88","author":"Huszar","year":"1997","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0640","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2337\/dc17-1867","article-title":"Leptin replacement reestablishes brain insulin action in the hypothalamus in congenital leptin deficiency","volume":"41","author":"Frank-Podlech","year":"2018","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.metabol.2024.156053_bb0645","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2337\/db15-1550","article-title":"Leptin substitution in patients with lipodystrophy: neural correlates for Long-term success in the normalization of eating behavior","volume":"65","author":"Schlogl","year":"2016","journal-title":"Diabetes"},{"issue":"46","key":"10.1016\/j.metabol.2024.156053_bb0650","doi-asserted-by":"crossref","first-page":"18276","DOI":"10.1073\/pnas.0706481104","article-title":"Leptin replacement alters brain response to food cues in genetically leptin-deficient adults","volume":"104","author":"Baicy","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.metabol.2024.156053_bb0655","doi-asserted-by":"crossref","first-page":"E1283","DOI":"10.1210\/jc.2010-2713","article-title":"Leptin therapy in a congenital leptin-deficient patient leads to acute and long-term changes in homeostatic, reward, and food-related brain areas","volume":"96","author":"Frank","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1\u20132","key":"10.1016\/j.metabol.2024.156053_bb0660","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1012947113197","article-title":"Leptin and the hypothalamic-pituitary regulation of the gonadotropin-gonadal axis","volume":"4","author":"Chan","year":"2001","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.metabol.2024.156053_bb0665","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa204","article-title":"The importance of leptin to reproduction","volume":"162","author":"Childs","year":"2021","journal-title":"Endocrinology"},{"issue":"16","key":"10.1016\/j.metabol.2024.156053_bb0670","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1523\/JNEUROSCI.0405-09.2009","article-title":"The ventral premammillary nucleus links fasting-induced changes in leptin levels and coordinated luteinizing hormone secretion","volume":"29","author":"Donato","year":"2009","journal-title":"J Neurosci"},{"issue":"9","key":"10.1016\/j.metabol.2024.156053_bb0675","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1073\/pnas.1621065114","article-title":"AgRP to Kiss1 neuron signaling links nutritional state and fertility","volume":"114","author":"Padilla","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.metabol.2024.156053_bb0680","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1210\/en.2014-1132","article-title":"Selective deletion of leptin receptors in gonadotropes reveals activin and GnRH-binding sites as leptin targets in support of fertility","volume":"155","author":"Akhter","year":"2014","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.metabol.2024.156053_bb0685","first-page":"2903","article-title":"Leptin and leptin receptor expression in normal and neoplastic human pituitary: evidence of a regulatory role for leptin on pituitary cell proliferation","volume":"84","author":"Jin","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156053_bb0690","article-title":"The role of the Adipokine leptin in immune cell function in health and disease","volume":"11","author":"Kiernan","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0695","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1038\/s41467-021-23220-x","article-title":"The metabolic hormone leptin promotes the function of T(FH) cells and supports vaccine responses","volume":"12","author":"Deng","year":"2021","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"10.1016\/j.metabol.2024.156053_bb0700","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cell.2017.12.001","article-title":"Leptin mediates a glucose-fatty acid cycle to maintain glucose homeostasis in starvation","volume":"172","author":"Perry","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.metabol.2024.156053_bb0705","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00774-014-0569-7","article-title":"Roles of leptin in bone metabolism and bone diseases","volume":"33","author":"Chen","year":"2015","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"10.1016\/j.metabol.2024.156053_bb0710","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.metabol.2014.10.021","article-title":"The role of leptin in regulating bone metabolism","volume":"64","author":"Upadhyay","year":"2015","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.metabol.2024.156053_bb0715","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/jcb.10156","article-title":"Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling","volume":"85","author":"Gordeladze","year":"2002","journal-title":"J Cell Biochem"},{"issue":"11","key":"10.1016\/j.metabol.2024.156053_bb0720","doi-asserted-by":"crossref","first-page":"E2252","DOI":"10.1210\/jc.2014-2491","article-title":"The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea","volume":"99","author":"Foo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2024.156053_bb0725","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1359\/jbmr.2002.17.2.200","article-title":"Leptin inhibits osteoclast generation","volume":"17","author":"Holloway","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.metabol.2024.156053_bb0730","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0092-8674(02)01049-8","article-title":"Leptin regulates bone formation via the sympathetic nervous system","volume":"111","author":"Takeda","year":"2002","journal-title":"Cell"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524002816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T22:14:38Z","timestamp":1731708878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524002816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":146,"alternative-id":["S0026049524002816"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156053","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence from clinical studies of leptin: current and future clinical applications in humans","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156053"}}